| Q67969961 | A case of prominent hepatic cholestasis developing to hepatic failure in lambda-AL amyloidosis |
| Q68896524 | AL amyloid deposits in temporal artery mimicking giant cell arteritis |
| Q73520756 | Acquired peripheral neuropathy |
| Q68128411 | Amyloid and amyloidosis |
| Q71791723 | Amyloidosis |
| Q77061406 | Amyloidosis |
| Q34722948 | Amyloidosis: prognosis and treatment |
| Q46802447 | An unusual cause of hepatorenal symptoms |
| Q40672382 | Anti-amyloid drugs: potential in the treatment of diseases associated with aging |
| Q36215543 | Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience |
| Q43203643 | Cholestasis and liver failure with lambda-AL amyloidosis |
| Q24186361 | Colchicine for prevention of cardiovascular events |
| Q40709737 | Colchicine in the treatment of AA and AL amyloidosis |
| Q68326147 | Colchicine therapy of the renal amyloidosis of ulcerative colitis |
| Q37772327 | Colchicine--expanding horizons |
| Q40846581 | De novo amyloidosis in a renal allograft: a case report and review of the literature |
| Q69919964 | Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component |
| Q79091946 | Etanercept therapy in patients with advanced primary amyloidosis |
| Q37773693 | Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population |
| Q31032765 | High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial |
| Q58220624 | Histomorphological patterns of renal amyloidosis: a correlation between histology and chemical type of amyloidosis |
| Q46400142 | How to manage primary amyloidosis |
| Q38970608 | Immunoglobulin Light Chain Systemic Amyloidosis |
| Q46700698 | Management and evaluation of localized amyloidosis of the bladder: two case reports |
| Q67945178 | Mitral regurgitation secondary to mitral valve involvement in cardiac amyloidosis |
| Q64361152 | Morphologic differences in the pattern of liver infiltration between systemic AL and AA amyloidosis |
| Q70235718 | Myopathy in primary systemic amyloidosis |
| Q78156195 | Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis |
| Q38240985 | Primary systemic amyloidosis--a diagnostic primer |
| Q74463869 | Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy |
| Q39852543 | Response of primary hepatic amyloidosis to melphalan and prednisone: a case report and review of the literature |
| Q37059137 | Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis |
| Q69597249 | Successful treatment of primary amyloidosis |
| Q36750220 | Systemic amyloidosis--three illustrative cases |
| Q46866143 | The premortem recognition of systemic senile amyloidosis with cardiac involvement |
| Q36115009 | The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone |
| Q35610846 | Therapy for immunoglobulin light chain amyloidosis: the new and the old. |
| Q51033339 | Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. |
| Q40623410 | Treatments for amyloidosis beyond symptomatic care |
| Q44468671 | Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. |
| Q33840304 | Use of subcutaneous abdominal fat biopsy specimen for detailed typing of amyloid fibril protein-AL by amino acid sequence analysis |